Investigational New Drugs **8:** 413–416, 1990.

CONTENTS VOL. 8, 1990

Antitumor activity and toxicity in animals of N-7[2(4-nitrophenyldithio)ethyl] mitomycin C (BMY-25067) – W.T. Bradner, W.C. Rose, J.E. Schurig, A.P. Florczyk S1

Schedule dependent potentiation of antitumor drug effects by a-difluoromethylornithine in human gastric carcinoma cells *in vitro* – S.C. Barranco, C.M. Townsend, Jr., B.Y. Ho, K.J. Reumont, S.K. Koester, P.J. Ford S9

Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines – A. Harstrick, J. Casper, H. Köhne-Wömpner, H. Wilke, H.-J. Schmoll, H. Poliwoda S19

Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30 – W.C. Rose, G.A. Basler, P.A. Trail, M. Saulnier, A.R. Crosswell, A.M. Casazza S25

Phase I study of tiazofurin (2-b-D-ribofuranosylthiazole-4-carboxamide, NSC 286193) – J.A. Maroun, D.J. Stewart S53

Phase I trial of a 5-day course of carbetimer – S.M. Grunberg, E. Ehler, R.B. Francis, Jr., M.S. Mitchell S41

A phase I and pharmacokinetic study of intravenous vinzolidine – C.W. Taylor, S.E. Salmon, W.G. Satterlee, A.B. Robertone, T.M. McCloskey, M.T. Holdsworth, P.M. Plezia, D.S. Alberts S51

Combination high-dose etoposide and vincristine infusion – D.V. Jackson, J.M. Cruz, D.R. White, H.B. Muss, A.R. Chauvenet S59

Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer – A. Mittelman, S. Savona, C. Puccio, H. Chun, T. Ahmed, E. Feldman, P. Sullivan, P. Arnold, Z. Arlin S65

Evaluation of menogaril in renal cell carcinoma: A Southwest Oncology Group phase II study (8504) – R.L. Stephens, P. Goodman, E.D. Crawford, C.F. Spicer, B.A. Lowe, F.R. Ahmann, R. Chapman, R.B. Natale S69

Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer – T. Umsawasdi, T.B. Felder, D. Jeffries, R.A. Newman S73

Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer – M.S. Simon, J. Eckenrode, R.B. Natale S79

A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma: A Southwest Oncology Group study – M.B. Edelstein, J.J. Crowley, F.A. Valeriote, J.D. Bonnet, J.O. Garden, R.C. Khanna, S.E. Salmon, J.S. Ungerleider S83

Phase II trial of intravenous mephalan for metastatic colorectal carcinoma: A Southwest Oncology Group study – W.A. Knight, III, P. Goodman, S.A. Taylor, J.S. Macdonald, C.A. Coltman, Jr., J.J. Constanzi, L.H. Baker S87

A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy: An Eastern Cooperative Oncology Group pilot study – D.L. Trump, J.C. Marsh, L.K. Kvols, D. Citrin, T.E. Davis, R.G. Hahn, S.E. Vogl S91

Phase II trials with flavone acetic acid (NSC 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma – S.B. Kaye, M. Clavel, P. Dodion, S. Monfardini, W. ten Bokkel-Huinink, D.T. Wagener, S. Gundersen, G. Stoter, J. Smyth, J. Renard, M. van Glabbeke, F. Cavalli S95

Fluorinated anthracyclines: synthesis and biological activity – K.C. Tonkin, R.T.C. Brownlee, F. Zunino, D.R. Philips 1

Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent – J.E. Schurig, W.C. Rose, H. Kamei, Y. Nishiyama, W.T. Bradner, D.A. Stringfellow 7

Discrepancy between cytotoxicity and DNA interstand crosslinking of carboplatin and cisplatin *in vivo* – W. DeNeve, F. Valeriote, E. Tapazoglou, C. Everett, A. Khatana, T. Corbett 17

Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs – Z. Zylicz, D.J.T. Wagener, M. Garzotto, T.B. Vree, E. van der Kleijn, L.A.G.M. van den Broek, H.C.J. Ottenheijm 25

Assessment of pulmonary and hematologic toxicities of Liblomycin, a novel bleomycin analog – R.A. Newman, Z.H. Siddik, E.L. Travis, D. Followill, W. Ayele, T. Burditt, I.H. Krakoff 33

Phase I study of oral menogaril administered on a once weekly schedule – D.J. Stewart, S. Verma, J.A. Maroun, L. Robillard, R.H. Earhart 43

Phase I study of oral spirogermanium – J. Harvey, M. McFadden, F.P. Smith, L. Joubert, P.S. Schein 53

Pyridoxine therapy for palmer-planter erythrodysesthesia associated with continuous 5-fluorouracil infusion – C.J. Fabian, R. Molina, M. Slavik, S. Dahlberg, S. Giri, R. Stephens 57

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer – a phase II study in elderly patients or patients with cardiac risk – H. Wilke, P. Preusser, U. Fink, W. Achterrath, L. Lenaz, M. Stahl, C. Schrober, H. Link, H.-J. Meyer, B. Lucke, H.-J. Schmoll 65

Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract – A.S. Goldenberg, D. Kelsen, J. Dougherty, G. Magill 71

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group Study – S.A. Taylor, T. Fleming, D.D. Von Hoff, J.D. McCracken, R.M. Bukowksi, R.W. Talley, R.B. Natale, J.T. Guy, W.E. Samlowski, J.H. Costanzi 77

Phase II evaluation of esorubicin (46 deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group Study – C.B. Vaughn, S.E. Salmon, T.R. Fleming 81

An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma – M.L. McMaster, F.A. Greco, D.H. Johnson, J.D. Hainsworth 87

VM-26 in colorectal carcinoma: A Southwest Oncology Group Study – N. Oishi, T.R. Fleming, L. Laufman, J.S. Ungerleider, R.B. Natale, A.B. Einstein Jr., D.D. Von Hoff, J.S. Macdonald 93

Phase II trial of 46deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma: An Illinois Cancer Council Study – C. Rose, T.E. Lad, L.J. Kilton, J. Schor, S.T. Rosen, A.H. Rossof, R.R. Blough, C.M. Johnson 97

Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group Study – C. Karanes, J. Crowley, L. Sawkar, B.L. Tranum, W.J. Hicks, J.D. Bonnet, L. Dabich, B.W. Dana, S. Salmon 101

A Southwest Oncology Group Study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck – D.E. Mattox, D.D. Von Hoff, S.P. Balcerzak 105

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck – H. Wheeler, R.L. Woods, J. Page, J. Levi 109

Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas – R.H. Earhart, D.J. Amato, A.Y. Chang, E.C. Borden, M. Shiraki, M.E. Dowd, R.L. Comis, T.E. Davis, T.J. Smith 113

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study – N.A. Iscoe, E.A. Eisenhauer, A.J. Bodurtha 121

A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma – H.B. Muss, N. Spell, D. Scudiery, R.L. Capizzi, M.R. Cooper, J. Cruz, D.V. Jackson, F. Richards II, C.L. Spurr, D.R. White, P.J. Zekan, A. Franklin 125

Cytotoxicity of diethyldithiocarbamate in human versus rodent cell lines – J.D. Cohen, H.I. Robins 137

In vitro activity of 46-iodo-46-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay – R. Villa, N. Zaffaroni, F. Giuliani, G. Colella, O. Sanfilippo, R. Silvestrini 143

Antitumor effect of GPA1734 in rat Walker 256 carcinoma – E. Missirlis, G. Karakiulakis, M.E. Maragoudakis 145

In vivo and *in vitro* pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats – J.M. Dornish, R.O. Larsen, P.E. Schwarze, B. Børretzen, E.O. Pettersen 149

A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infusion schedule – C.J. Allegra, J. Jenkins, R.B. Weiss, F. Balis, J.C. Drake, J. Brooks, R. Thomas, G.A. Curt 159

Phase I evaluation of diaziquone in childhood cancer: *A Pediatric Oncology Group study* – J.M. Falletta, B. Cushing, S. Lauer, B. Bell, D.H. Mahoney, R. Castleberry, R.A. Krance 167

Phase I trial of tallysomycin S_{10b}, a bleomycin analogue – F.P. Paolozzi, R.C. Gaver, N.B. Newman, B.J. Poiesz, S. DeFino, A. Louie, R.L. Comis 171

Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas – F.M. Balis, A. Gillespie, J. Belasco, G.H. Reaman, L.J. Ettinger, R.F. Murphy, K. Doherty, S. Jeffries, M.E. Horowitz, D.G. Poplack 181

Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer – D.S. Ettinger, D.M. Finkelstein, M.D. Abeloff, Y-C. Chang, T.J. Smith, M.M. Oken, J.C. Ruckdeschel 183

Phase II trial of carboplatin in patients with advanced melanoma – E.S. Casper, D. Bajorin 187

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer: *A Gynecologic Oncology Group study* – W.P. McGuire, III, J.A. Blessing, J.S. Berek, A. Munoz 191

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix: *A Gynecologic Oncology Group study* – W.P. McGuire, III, J.A. Blessing, K.D. Hatch, M.L. Berman 195

Phase II study of Fludarabine Phosphate in multiple myeloma: A Southwest Oncology Group study – E.H. Kraut, J.J. Crowley, M.R. Grever, M.D. Keppen, J.D. Bonnet, H.E. Hynes, S.E. Salmon 199

Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma – D.L. Trump, P. Elson 201

5-Day vinblastine infusion for pancreatic adenocarcinoma: *A phase II Southwest Oncology Group study* – J.T. Guy, T. Fleming, T.W. Pollock, S.E. Rivkin, R.P. Pugh, H. Saiers, H.E. Hynes, J.F. Boyd 205

Pirarubicin (4ó-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer: *A Clinical Phase II study* – W. Scheithauer, H. Samonigg, D. Depisch, J. Schüller, H. Hausmaninger, J. Wiegele, C. Zielinsky, H. Stöger, K. Haider, P. Preis, W. Seidl, B. Greifenberg, H. Ludwig 207

Hypersensitivity reactions to trimetrexate – J.L. Grem, S.A. King, M.E. Costanza, T.D. Brown 211

Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer – G. Falkson, M.R. Chasen, H.C. Falkson 215

Clinical cardiotoxicity of esorubicin (4ó-deoxydoxorubicin, DxDx): Prospective studies with serial gated heart scans and reports of selected cases: *A Cancer and Leukemia Group B report* – Q.S. Ringenberg, K.J. Propert, H.B. Muss, R.B. Weiss, R.L. Schilsky, C. Modeas, M.C. Perry, L. Norton, M. Green 221

Clinical toxicity associated with tiazofurin – J.L. Grem, L. Rubinstein, S.A. King, B.D. Cheson, M.J. Hawkins, D.D. Shoemaker 227

Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer – J.F. Worzalla, J.R. Bewley, G.B. Grindey 241

Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice – P. Mucci-LoRusso, L. Polin, L.A. Biernat, F.A. Valeriote, T.H. Corbett 253

Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) *in vitro* against human colon cancer cells – S.S. Neelam, A. Bernabei, C. Freedland, R. Thompson, T.H. Corbett, G.D. Luk 263

Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule – D.R. Budman, W. Kreis, J. Behr, P. Schulman, S. Lichtman, S.L. Allen, L. Weiselberg, W.G. Satterlee, R.L. Nelson, V. Vinciguerra 269

Phase I study of idarubicin administered orally on a daily · 3 schedule – D.J. Stewart, S. Verma, J.A. Maroun, L. Robillard, D.J. Perrault, V. Young, S. Gupta and B. Fontaine 275

Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study – E.A. Eisenhauer, K.I. Pritchard, D.J. Perrault, S. Verma, J.L. Pater 283

Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer – M.J. Kennedy, R.C. Donehower, L.B. Grochow, D.S. Ettinger, J.H. Fetting, M.D. Abeloff 289

A phase II study of menogaril (NSC-269148) in colorectal carcinoma: A Southwest Oncology Group study – R.P. Whitehead, R.H. Earhart, T. Fleming, P. Goodman, J.S. Macdonald, T. Pollock, J.S. Ungerleider 295

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer – J.S. Lee, H.I. Libshitz, W.K. Murphy, D. Jeffries, W.K. Hong 299

A phase II study of mitoxantrone in advanced gastric cancer – J.A. Levi, P.G. Gill, P. Presgrave 305

Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma: A Southwest Oncology Group study – J.P. Kuebler, P.J. Goodman, T.D. Brown, E.D. Crawford, C.L. Reitz, W.A. Knight III, J.A. Kish 307

A phase II trial of echinomycin in metastatic cervix carcinoma – T. Hakes, M. Markman, M. Phillips 311

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: An Illinois Cancer Council phase II study – N.J. Vogelzang, V.J. Lanzotti, B. Muntean, R.R. Blough 313

Phase II study of Fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma – M.R. Modiano, W.S. Dalton, S.M. Lippman, L. Joffe, A.R. Booth, F.L. Meyskens, Jr. 317

Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach – D. Ginn, D. Kelsen, M. Eisenberger, R. Heelan, G. Magill 321

Phase II study of tallysomycin $S_{10}b$ in patients with advanced head and neck cancer – C. Nicaise, W.K. Hong, W. Dimery, J. Usakewicz, M. Rosencweig, I. Krakoff 325

Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma: Results of an Eastern Cooperative Oncology Group study (EST 2685) – H. Hochster, M. Hunt, M. Green, D. Parkinson, T. Smith 329

Phase II study of esorubicin (4ó deoxydoxorubicin) in anthracycline naive patients with ovarian cancer – M.D. Green, J.L. Speyer, J.C. Wernz, N. Colombo, U. Beller, F.M. Muggia, E.M. Beckman 333

Evaluation of a platinum-doxorubicin complex in experimental tumor systems – F. Zunino, G. Pratesi, F. Formelli, A. Pasini 341

A semi-automated neutral red based chemosensitivity assay for drug screening – P.F. Cavanaugh Jr., P.S. Moskwa, W.H. Donish, P.J. Pera, D. Richardson, A.P. Andrese 347

Fluorinated anthracyclines: interactions with DNA – K.C. Tonkin, R.C. Boston, R.T.C. Brownlee, D.R. Phillips 355

Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function – B.A. Conley, M.J. Egorin, V. Sinibaldi, D.A. Van Echo 365

3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity – K. Margolin, J. Doroshow, L. Leong, S. Akman, B. Carr, O. Odujinrin, B. Flanagan, W. Grove, R. DeLap, D. Goldberg 369

Phase II trial of vinblastine in advanced ovarian carcinoma: *A Gynecologic Oncology Group study* – G.P. Sutton, J.A. Blessing, M.D. Adelson, P. Hanjani 377

Phase II trial of echinomycin in advanced soft tissue sarcomas: *A Southwest Oncology Group study* – S.A. Taylor, B. Metch, S.P. Balcerzak, K.H. Hanson 381

Phase II study of carbetimer in non-small cell lung cancer – M. Keaton, T. Brown, J. Craig, G. Fries, G. Harmon, A. Zaloznik, G. Orczyk, D. Von Hoff 385

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas: *A phase II study of the Northern California Oncology Group* – R.W. Carlson, J.H. Doroslow, O.O. Odujinrin, M.S. Flam, M. Malec, K.R. Lamborn 387

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma – R. Motzer, H. Scher, D. Bajorin, C. Sternberg, G.J Bosl 391

4′-EPI-doxorubicin in advanced lung cancer. *A phase II trial* – G. Giaccone, M. Donadio, G. Bonardi, W. Iberti, A. Calciati 393

Phase II study of lonidamine in patients with metastatic breast cancer: *An Eastern Cooperative Oncology Group study* – H.I. Robins, D.S. Neuberg, A.B. Benson, III, K.J. Pandya, D.C. Tormey 397

Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. *A Pediatric Oncology Group phase II study* – R.P. Castleberry, A.H. Ragab, C.P. Steuber, B. Kamen, S. Toledano, K. Starling, D. Norris, P. Burger, J.P. Krischer 401

High versus low dose granisetron, a selective $5HT_3$ antagonist, for the prevention of chemotherapy-induced nausea and vomiting – H.C. Falkson, C.I. Falkson, G. Falkson 407